Organic Letters
Letter
34, 1833. (e) Schuster, M.; Blechert, S. L. Angew. Chem., Int. Ed. Engl.
1997, 36, 2036. (f) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54,
̈
4413. (g) Furstner, A. Top. Organomet. Chem. 1998, 1, 37. (i) Schrock,
R. R. Top. Organomet. Chem. 1998, 1, 1. (i) Schrock, R. R.
Tetrahedron 1999, 55, 8141. (j) Blechert, S. Pure Appl. Chem. 1999,
71, 1393. (k) Wright, D. L. Curr. Org. Chem. 1999, 3, 211. (l) Maier,
(10) (a) Willumstad, T. P.; Boudreau, P. D.; Danheiser, R. L. J. Org.
Chem. 2015, 80, 11794. (b) Majhail, M. J.; Ylioja, P. M.; Willis, M. C.
Chem. - Eur. J. 2016, 22, 7879.
(11) Kuhn, K. M.; Champagne, T. M.; Hong, S. H.; Wei, W.-H.;
Nickel, A.; Lee, C. W.; Virgil, S. C.; Grubbs, R. H.; Pederson, R. L.
Org. Lett. 2010, 12, 984.
(12) (a) Ismail, F. M. D. J. Fluorine Chem. 2002, 118, 27.
(b) Biomedical Frontiers of Fluorine Chemistry; Ojima, I., McCarthy, J.
R., Welch, J. T., Eds.; ACS Symposium Series 639; American
Chemical Society: Washington, DC, 1996. (c) Welch, J. T.;
Eswarakrishnan, S. Fluorine in Bioorganic Chemistry; Wiley: New
York, 1991. (d) Enantiocontrolled Synthesis of Fluoro-organic Biomedical
Targets; Soloshonok, V. A., Ed.; Wiley: New York, 1999.
(13) (a) Salim, S. S.; Bellingham, R. K.; Satcharoen, V.; Brown, R. C.
D. Org. Lett. 2003, 5, 3403. (b) Marhold, M.; Buer, A.; Hiemstra, H.;
van Maarseveen, J. H.; Haufe, G. Tetrahedron Lett. 2004, 45, 57.
(c) De Matteis, V.; van Delf, F. L.; Tiebes, J.; Rutjes, F. P. J. T. Eur. J.
Org. Chem. 2006, 2006, 1166. (d) De Matteis, V.; van Delf, F. L.;
Jakobi, H.; Lindell, S.; Tiebes, J.; Rutjes, F. P. J. T. J. Org. Chem. 2006,
71, 7527. (e) De Matteis, V.; van Delf, F. L.; de Gelder, R.; Tiebes, J.;
Rutjes, F. P. J. T. Tetrahedron Lett. 2004, 45, 959. (f) De Matteis, V.;
Dufay, O.; Waalboer, D. C. J.; van Delf, F. L.; Tiebes, J.; Rutjes, F. P.
J. T. Eur. J. Org. Chem. 2007, 2007, 2667. (g) De Matteis, V.; van Delf,
F. L.; Tiebes, J.; Rutjes, F. P. J. T. Synlett 2008, 3, 351. (h) Marhold,
M. E. Angew. Chem., Int. Ed. 2000, 39, 2073. (m) Furstner, A. Angew.
̈
Chem., Int. Ed. 2000, 39, 3012. (n) Roy, R.; Das, K. Chem. Commun.
2000, 519. (o) Schrock, R. R.; Hoveyda, A. H. Angew. Chem., Int. Ed.
2003, 42, 4592. (p) Deiters, A.; Martin, S. F. Chem. Rev. 2004, 104,
2199. (q) Schrock, R. R. Angew. Chem., Int. Ed. 2006, 45, 3748.
(r) Grubbs, R. H. Angew. Chem., Int. Ed. 2006, 45, 3760.
(s) Samojłowicz, C.; Grela, K. Chem. Rev. 2009, 109, 3708.
(t) Vougioukalakis, G. C.; Grubbs, R. H. Chem. Rev. 2010, 110,
́
1746. (u) Guerin, D.; Gaumont, A.-C.; Dez, I.; Mauduit, M.; Couve-
Bonnaire, S.; Pannecoucke, X. ACS Catal. 2014, 4, 2374.
(4) For disubstituted cyclic olefin: See ref 3a−b. For cyclic
trisubstituted olefin: (a) Chatterjee, A. K.; Grubbs, R. H. Org. Lett.
1999, 1, 1751. (b) Chatterjee, A. K.; Sanders, D. P.; Grubbs, R. H.
Org. Lett. 2002, 4, 1939. For tetrasubstituted olefins: (c) Ackermann,
L.; Furstner, A.; Weskamp, T.; Kohl, F. J.; Herrmann, W. A.
̈
Tetrahedron Lett. 1999, 40, 4787. (d) Liang, Y.; Raju, R.; Le, T.;
Taylor, C. D.; Howell, A. R. Tetrahedron Lett. 2009, 50, 1020.
(e) White, D. E.; Stewart, I. C.; Grubbs, R. H.; Stoltz, B. M. J. Am.
Chem. Soc. 2008, 130, 810.
̈
M.; Stillig, C.; Frohlich, R.; Haufe, G. Eur. J. Org. Chem. 2014, 2014,
5777. (i) Cogswell, T. J.; Donald, C. S.; Long, D. L.; Marquez, R. Org.
Biomol. Chem. 2015, 13, 717. (j) Donohoe, T. J.; Fishlock, L. P.;
Procopiou, P. A. Org. Lett. 2008, 10, 285.
(5) For several articles performed on dimethyl group, see: (a) Scholl,
M.; Trnka, T. M.; Morgan, J. P.; Grubbs, R. H. Tetrahedron Lett.
̈
1999, 40, 2247. (b) Furstner, A.; Thiel, O. R.; Ackermann, L.; Schanz,
(14) Gatti, M.; Drinkel, E.; Wu, L.; Pusterla, I.; Gaggia, F.; Dorta, R.
J. Am. Chem. Soc. 2010, 132, 15179.
(15) Hoveyda−Grubbs II catalyst did not show any activities toward
the formation of tetrasubstituted cyclic fluoro- or trifluoromethylated
olefins.
(16) Analysis of residual ruthenium level showed a low amount of
ruthenium (4.1−5.3 ppm) for 8q and 9b (see Supporting
(17) Chelation of the ruthenium complex by the sulfide or the
disfavored torsion angle could be the cause of this result. See:
(a) Shon, Y. L.; Lee, T. R. Tetrahedron Lett. 1997, 38, 1283.
(b) Spagnol, G.; Heck, M. P.; Nolan, S. P.; Mioskowski, C. Org. Lett.
2002, 4, 1767.
H. J.; Nolan, S. P. J. Org. Chem. 2000, 65, 2204. (c) Yao, Q.; Zhang, Y.
J. Am. Chem. Soc. 2004, 126, 74. (d) Michrowska, A.; Bujok, R.;
Harutyunyan, S.; Sashuk, V.; Dolgonos, G.; Grela, K. J. Am. Chem. Soc.
2004, 126, 9318. (e) Yao, Q.; Sheets, M. J. Organomet. Chem. 2005,
690, 3577. (f) Berlin, J. M.; Campbell, K.; Ritter, T.; Funk, T. W.;
Chlenov, A.; Grubbs, R. H. Org. Lett. 2007, 9, 1339. (g) Stewart, I. C.;
Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y. Org.
Lett. 2007, 9, 1589. (h) Rost, D.; Porta, M.; Gessler, S.; Blechert, S.
Tetrahedron Lett. 2008, 49, 5968. (i) Peeck, L. H.; Plenio, H.
Organometallics 2010, 29, 2761. (j) Sashuk, V.; Peeck, L. H.; Plenio,
H. Chem. - Eur. J. 2010, 16, 3983. (k) Paek, S. M. Molecules 2012, 17,
3348.
(6) (a) Burke, M. D.; Schreiber, S. L. Angew. Chem., Int. Ed. 2004,
43, 46. (b) Diversity-Oriented Synthesis: Basics and Applications in
Organic Synthesis, Drug Discovery, and Chemical Biology; Trabocchi, A.,
Ed.; John Wiley & Sons: New York, 2013.
(7) (a) Arcadi, A.; Chiarini, M.; Del Vecchio, L.; Marinelli, F.;
Michelet, V. Eur. J. Org. Chem. 2017, 2017, 2214. (b) Tomas-
Mendivil, E.; Heinrich, C.; Ortuno, J.-C.; Starck, J.; Michelet, V. ACS
Catal. 2017, 7, 380. (c) Arcadi, A.; Chiarini, M.; Del Vecchio, L.;
Marinelli, F.; Michelet, V. Chem. Commun. 2016, 52, 1458. (d) Arcadi,
A.; Pietropaolo, E.; Alvino, A.; Michelet, V. Org. Lett. 2013, 15, 2766.
(e) Mariaule, G.; Newsome, G.; Toullec, P. Y.; Belmont, P.; Michelet,
V. Org. Lett. 2014, 16, 4570. (f) Tang, Y.; Benaissa, I.; Huynh, M.;
(18) Dong, X.; Sang, R.; Wang, Q.; Tang, X.-Y. Chem. - Eur. J. 2013,
19, 16910.
(19) (a) Vinyl chloride 14b was accompanied with 36% of
homocoupling product. (b) Silyl enol ether 14c was accompanied
with 42% of isomerized-thermodynamic silyl enol ether and 13% of
cross-metathesis product.
(20) (a) Aggarwal, V. K.; Daly, A. M. Chem. Commun. 2002, 2490.
(b) Hoshi, M.; Kaneko, O.; Nakajima, M.; Arai, S.; Nishida, A. Org.
Lett. 2014, 16, 768. (c) Chao, W.; Weinreb, S. M. Org. Lett. 2003, 5,
2505. (d) Chao, W.; Meketa, M. L.; Weinreb, S. M. Synthesis 2004,
2004, 2058. (e) Korboukh, I.; Kumar, P.; Weinreb, S. M. J. Am. Chem.
Soc. 2007, 129, 10342.
(21) (a) Renaud, J.; Ouellet, S. G. J. Am. Chem. Soc. 1998, 120, 7995.
(b) Morrill, C.; Funk, T.; Grubbs, R. H. Tetrahedron Lett. 2004, 45,
7733. (c) Altenhofer, E.; Harmata, M. Org. Lett. 2014, 16, 3.
(22) Thakur, A.; Zhang, K.; Louie, J. Chem. Commun. 2012, 48, 203.
(23) Rauniyar, V.; Zhai, H.; Hall, D. G. J. Am. Chem. Soc. 2008, 130,
8481.
́
Vendier, L.; Lugan, N.; Bastin, S.; Belmont, P.; Cesar, V.; Michelet, V.
Angew. Chem., Int. Ed. 2019, 58, 7977. (g) Chen, X.; Martini, S.;
Michelet, V. Adv. Synth. Catal. 2019, 361, 3612.
(8) (a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem.
2014, 57, 10257. (b) Holladay, M. W.; Dart, M. J.; Lynch, J. K. J. Med.
Chem. 1997, 40, 4169. (c) Chow, K.; Heidelbaugh, T.; Nguyen, P.;
Sinha, S. (Allergan Inc, USA) WO 2,007,005,177; November 1, 2007.
(d) Brown, B. S.; Keddy, R.; Zheng, G. Z.; Schmidt, R. G.; Koenig, J.
R.; McDonald, H. A.; Bianchi, B. R.; Honore, P.; Jarvis, M. J.; Surowy,
C. S.; Polakowski, J. S.; Marsh, K. C.; Faltynek, C. R.; Lee, C. H.
̈
Bioorg. Med. Chem. 2008, 16, 8516. (e) Bottcher, H.; Barnickel, G.;
Hausberg, H. H.; Haase, A. F.; Seyfried, C. A.; Eiermann, V. J. Med.
Chem. 1992, 35, 4020. (f) Manning, A. S.; Chatelain, P. P. U.S. Patent
́
5,378,709, Jan. 3, 1995. (g) Magana-Garcia, M.; Arista-Viveros, A.
Pediatr. Dermatol. 1993, 10, 352.
D
Org. Lett. XXXX, XXX, XXX−XXX